Medivation Inc  

(Public, NASDAQ:MDVN)   Watch this stock  
Find more results for mdvn
81.44
Sep 28 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 26.41 - 81.48
Open     -
Vol / Avg. 0.00/6.93M
Mkt cap 13.52B
P/E     -
Div/yield     -
EPS -1.17
Shares 165.93M
Beta 0.60
Inst. own 91%
Nov 3, 2016
Q3 2016 Medivation Inc Earnings Release (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '16) 2015
Net profit margin -195.92% 25.94%
Operating margin -303.47% 41.72%
EBITD margin - 44.70%
Return on average assets -108.55% 20.89%
Return on average equity -225.98% 37.02%
Employees 628 -
CDP Score - -

Address

525 Market St Fl 36
SAN FRANCISCO, CA 94105-2747
United States - Map
+1-415-5433470 (Phone)
+1-415-5433411 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Medivation, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company, in collaboration with Astellas Pharma, Inc. (Astellas), has one commercial product, XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States, Europe and other countries across the world for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company, in collaboration with Astellas, is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. It has developed a small molecule inhibitor of the sterol regulatory element-binding protein, or SREBP, pathway which it refers to as MDV4463.